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1. Introduction
The hypermetabolic nature of post-traumatic brain injury (TBI) state makes adequate nutri‐
tional support critical. Maintenance of adequate nutritional intake has been shown to have a
significant impact on outcomes after TBI. [1] While pre-injury and immediate post-injury
malnutrition has been associated with lower survival after TBI, much remains to be learned
about the role and optimization of nutritional support beyond the initial phases of recovery.
One of the most rapidly evolving aspects of clinical investigation in this general area is focusing
on the effects of immune-modulating nutrition on TBI outcomes. The secondary injury phase
following brain trauma is characterized by neuroinflammation, free radical generation,
excitatory toxicity, and oxidative stress. [2] In this chapter we will present our current state of
understanding of immune-nutrition for TBI, highlighting modern clinical practices and
emerging trends. Many nutritional supplements have shown promise in preclinical and animal
trials, particularly in the area of neuroprotection prior to injury, but human clinical trials have
been largely disappointing or nonexistent.
2. General overview of nutritional support following TBI
Trauma, including TBI, is associated with transient immune-suppression and high rates of
nosocomial infection. Gastrointestinal mucosal health quickly deteriorates following trauma
and stress.[3] Immune-modulating nutrition has been associated with lower complication and
infection rates in surgical and critically ill patients and is recommended in SCCM and ASPEN
guidelines for select patients including trauma patients. [4] These guidelines make broad
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recommendations for the initiation and management of enteral nutrition in critical illness and
should serve as the evidence-based foundation for nutritional support programs. Early
administration of enteral feeding, combined with immune-modulating nutrient supplemen‐
tation, has been shown to promote both the structural integrity and immunological function
of the gastrointestinal mucosa. Target caloric and protein intake goals should be calculated for
each patient, accommodating fully for any baseline increases in nutritional needs due to the
metabolic stress of injury. The general initial nutritional strategy should include the provision
of more than 50 percent of the estimated total energy expenditure and 1–1.5 g/kg protein within
24 hours of injury. [5] The provision of these requirements by the enteral rather than the
parenteral route is always preferred.
3. The immune-enhancing paradigm
Immune-enhancing nutritional ingredients will be the focus of the subsequent sections of this
chapter. Specifically, we will discuss the use of omega-3 fatty acids, dietary nucleotides,
arginine, glutamine, and various antioxidants in TBI. General principles of the immune-
enhancing paradigm focus on aggressive supplementation of immune-modulating ingredients
with the aim of promoting healing of injured brain tissue and minimizing loss of parenchyma
in the area of penumbra—the threatened but still viable tissue around the periphery of acute
brain injury[6]. Many immune-modulating strategies (including steroid administration in
CRASH I) have been trialed, frequently without demonstrating benefit[7]. Protocols for the
timing, dosage, and route for many of these immune-modulating elements are yet to be clearly
defined, and the authors will focus on the most up-to-date evidence regarding the basic science
and clinical research on this topic.
4. Omega-3 fatty acids
Omega-3 fatty acids (n-3FAs) such as eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA) have been shown to be of potential value in the management of patients with TBI.
Present in dietary intake, n-3FAs are commonly found in fish oils and are associated with a
wide range of possible health benefits. The human brain is composed of 60% lipid by dry
weight, with DHA representing one of the most abundant fatty acids found in the brain. [2]
N-3FAs contribute to membrane fluidity and thus affect many different aspects of neuronal
development and physiology, including cell adhesion, axon guidance, synaptic integrity, and
neurotransmission. [2] Additionally, n-3FAs may also play a role in defense against oxidative
stress and inflammation.
Biological pathways
N-3FAs have been shown to mitigate the consequences of several key pathologic cellular
pathways associated with TBI, including oxidative stress, apoptosis, inflammation, and
neuronal excitotoxicity. [2]
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• In response to disruption of neuronal membranes, arachidonic acid is released and con‐
verted to pro-inflammatory prostaglandins. N-3FA derivatives, on the other hand, inhibit
activation and migration of inflammatory cells. Physiologically, n-3FAs also suppress T-cell
activation and natural killer cell activity and decrease the total number of circulating
leukocytes. [2]
• In the setting of acute oxidative stress, DHA has been demonstrated to lessen the burden of
lipid and protein peroxidation. Its metabolites can also modulate expression of tissue repair
signals, upregulate anti-apoptotic proteins, and downregulate pro-apoptotic proteins. [8]
• The excitotoxic neurotransmitter glutamate is released following TBI, leading to a dispro‐
portionate influx of calcium into neurons and subsequent cell death. [2] In vitro, DHA has
been shown to decrease calcium influx and thus lessen the burden of glutamate cytotoxicity.
Cumulatively, the effects of n-3FAs on TBI-related cellular processes may promote cell survival
and viability, highlighting the potential role of n-3FAs in improving neurological outcomes.
Animal studies
Animal studies investigating the role of n-3FAs in experimental TBI models have produced
encouraging results.
• In rat fluid percussion injury (FPI) models, n-3FAs have been shown to decrease oxidative
damage as measured by protein oxidation, improve post-traumatic cognitive disability as
measured by water maze testing, and normalize dysregulated expression of genes linked
to neuronal energy homeostasis. [9, 10]
• In a rat model of controlled cortical impact (CCI), n-3FAs were shown to restore TBI-induced
deficits in neuronal dopamine release, important for maintenance of learning, attention, and
other neurobehavioral phenomena. [2, 11]
• Finally, in response to impact acceleration TBI in rats, dietary DHA supplementation has
been linked to decreased neuronal injury and decreased caspase-3 activity, a marker of
apoptosis. [12-14]. Conversely, dietary deficiency of n-3FAs in animal models has been
associated with impaired neurogenesis, decreased neuronal size, and neurobehavioral
defects. [2] In rat models, n-3FA deficiency has been specifically connected with increased
spinal cord vulnerability to neuronal damage, measured by reduced markers of synaptic
plasticity and membrane homeostasis in the lumbar spinal cord. [15]
Clinical studies
Despite the laboratory and animal research showing potential benefits of n-3FAs in improving
clinical outcomes following TBI, there have been no clinical trials to verify such benefits in
human subjects. There have been promising case reports of n-3FA use in TBI and a pilot study
which suggested a link between n-3FAs and prevention of post-traumatic psychiatric distress
[16, 17], but more robust studies of clinical response will be necessary to ascertain therapeutic
benefit. Challenges to conducting effective studies include inconsistent doses and sources of
commercially-available n-3FA preparations. Various trials use different doses of n-3FA and
the sources are inconsistent as suppliers vary the species of fish used to make fish oils. Low
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doses of n-3FA are incorporated in many commercial fish oils but experimental TBI studies
typically have focused on higher dose supplementation. [18] Each product also has its own
ratio of DHA and EPA. Two prescription n-3FA products are available in the United States,
but both primarily consist of EPA.
Clinical Limitations
The clinical use of dietary n-3FAs for TBI has been historically limited by concerns for anti-
thrombotic actions, but this concern has subsided with several studies in cardiology patients
using combination regimens of fish oil and antiplatelet agents. [19, 20] Other threats to the
n-3FA supply, including heavy metal toxicity in some fish oils, also confound the field.
5. Dietary oligonucleotides
Following traumatic brain injury, nucleotides are released into the extracellular space, acting
in both an autocrine and paracrine fashion, via nucleotide receptors on neuronal cells. [21]
From individual nucleosides to antisense strands and microRNAs, dietary oligonucleotides
represent a possible therapeutic means through which the pathophysiological responses and
functional outcomes of TBI can be modulated. [22]
Biological pathways
Much work has been done at the single nucleoside level, specifically focusing on the role
of adenosine. Adenosine is a purine nucleoside, speculated to play a neuroprotective role
in  TBI,  leading  to  lower  neuronal  metabolism  and  greater  cerebral  blood  flow.  [23]
Adenosine and its metabolic derivatives have been shown to acutely upregulate after TBI
in both animal models  and human disease.  [24-27]  A product  of  ATP breakdown, cere‐
bral  adenosine  acts  via  the  purinergic  signaling  system  and  may  reduce  cellular  death
related  to  glutamate-mediated  excitotoxicity.  It  also  decreases  free  radical-related/oxida‐
tive damage. [28] Although different adenosine receptors have been observed to facilitate
both beneficial  and deleterious physiologic effects in post-TBI studies,  adenosine and its
downstream pathways remain clearly linked to the pathophysiology of TBI and represent
possible targets for therapeutic modulation. [21, 29-33]
Antisense oligonucleotides, on the other hand, are short synthetic nucleotide strands that
can bind to specific messenger RNA (mRNA) targets, making them susceptible to degrada‐
tion and thus effectively blocking synthesis of corresponding proteins. [34] These nucleoti‐
des  represent  yet  another  promising  avenue  through  which  novel  TBI  management
strategies can begin to utilize more recent biomedical research discoveries.
Animal studies
Animal  TBI  studies  involving  oligonucleotide-based  therapies  have  produced  some
promising results.  Oligomeric diets  demonstrated potential  benefit  in rat  models of  TBI,
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preventing  TBI-induced  weight  loss  and  thymus  atrophy  and,  by  extension,  averting
immune dysfunction. [35]
In terms of specific nucleosides, adenosine is increased in rat fluid percussion injury (FPI)
and controlled cortical impact (CCI) models of TBI, and 2-chloroadenosine, an adenosine
analogue,  has  been  demonstrated  to  confer  improved  bioenergetic  and  functional  out‐
comes after FPI. [27] Additionally, in a weight-drop closed head injury (CHI) TBI model,
intraperitoneal injection of cytidine triphosphate (CTP) has been shown to decrease neuronal
apoptosis and improve motor function post-TBI. [36]
Antisense oligonucleotides have also been studied in animal models of TBI.
• In a rat stab wound model of brain injury, antisense oligonucleotides against a mono‐
cyte  chemoattractant  protein  (MCP-1)  were  able  to  inhibit  inflammatory  chemokine
production. [37]
• In a rat  FPI model,  pretreatment with antisense oligonucleotides against a specific N-
methyl-D-aspartate (NMDA) glutamate receptor (NMDA-R1) decreased mortality from
50%  to  8%  and  improved  behavioral  recovery,  both  likely  due  to  the  prevention  of
glutamate excitotoxicity. [38]
• In a murine weight-drop CHI TBI model, injection of oligonucleotides against acetylcho‐
linesterase  (AChE)  reduced  mortality  from  50%  to  20%  in  trauma-sensitive  mice,
decreased post-TBI neuronal death, and improved neuromotor recovery as measured via
a beam test for balance and coordination. [34]
Clinical studies
While no clinical studies have explored the use of oligonucleotide-based therapies for TBI,
associations have been made in humans between TBI severity and increased CSF concentra‐
tions  of  adenosine.  [23,  27]  Clinical  concerns  of  oligonucleotide  treatments  include  the
cardiovascular effects of purinergic modulation and the effects of oligonucleotides on other
unrelated receptor targets. Certainly the array of cell-based and animal studies highlight
clear potential for the translational relevance of dietary oligonucleotides. [33, 34]
6. Arginine
Arginine is a nonessential amino acid and is a component of both enteral and parenteral
nutrition formulas.  [39]  Normally,  arginine homeostasis  is  driven by dietary intake and
metabolic degradation, and when its utilization increases during growth, development, or
injury,  arginine  may be  recognized  as  an  essential  amino  acid.  [39]  Parenteral  arginine
supplementation  in  trauma patients  has  been  demonstrated  to  confer  improved wound
healing and immune responses and has no known adverse effects as a nutritional supple‐
ment.  [39]  From  this  background,  and  given  that  serum  levels  of  L-arginine  and  its
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metabolites  have  been  shown  to  be  significantly  reduced  in  patients  post-TBI,  arginine
represents a potential dietary adjuvant to enhance TBI therapy. [40]
Biological pathways
L-arginine is the immediate, endogenous precursor of nitric oxide (NO), an important
physiological vasodilator. [41] Immediately post-TBI, there is an increase of NO, followed by
a sustained decrease which can result in diminished cerebral blood flow (CBF) and consequent
hypoperfusion. [42] Additionally, arginine is a precursor for proline and 4-hydroxyproline –
both important for extracellular matrix (ECM) remodeling – and for creatine – an important
energy source in both muscle and brain tissues that will be discussed independently later in
this chapter. [40]
Animal studies
Administration of L-arginine has been shown in both rat and mouse controlled cortical impact
(CCI) models to restore CBF and reduce contusion volume post-TBI in a dose-dependent
manner. [40, 41, 43-48] It has been also been demonstrated in a rat fluid percussion injury (FPI)
model to reduce immunoreactivity for nitrotyrosine, a marker of peroxynitrite (ONOO-) super
oxide radicals. [49, 50] While one study failed to confirm that hypertonic arginine produced
significant cerebrovascular improvements over hypertonic saline in a rat FPI model, other dose
and time studies in rats have even shown that L-arginine is most neuroprotective when 300mg/
kg is given as soon as possible after injury. [39, 51] Rats treated with an arginase-specific
inhibitor (Nω-hydroxy-nor-arginine) showed significantly reduced contusion volume post-
TBI. [45]
Clinical studies and limitations
There have been no clinical studies exploring the potential therapeutic benefits of isolated
arginine supplementation in post-TBI patients. Arginine is a common ingredient in commer‐
cially-available formulas and in low doses it appears to be safe. Trials of critical care formulas
including arginine, fish oil, and various antioxidants appear to be safe and are effective at
reducing infection rates in TBI and other critically-ill patients. [52] Although arginine seems
to have strong translational promise, a number of potential risks exist before considering
hyper-supplementation of arginine. For instance, while some studies have linked L-arginine
to reduced neuronal damage, none have been able to demonstrate the same beneficial effects
with regards to neurological function. [43] Secondly, the optimal dose of 300 mg/kg in rats is
much larger than amounts of arginine found in typical nutritional formulations. [39] Finally,
the roles of other arginine derivatives, such as arginine vasopressin, and nitric oxide (NO)
signaling remain unclear in post-TBI pathophysiology. [46, 53-64]
7. Glutamine
Glutamine is a non-essential amino acid, widely distributed throughout the body. It is the most
abundant free amino acid in circulation. [65, 66] Glutamine synthesis cannot keep up with
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increased requirements such as those experienced during physiological stress, yet it is
important for the immune response. Consequently, glutamine supplementation has been
shown to decrease infectious complications in trauma patients. [65, 66] The brain serves
prominently in glutamine metabolism and is a net producer of the amino acid. [67] In the brain,
glutamine is involved in the glutamine-glutamate cycle which functions to conserve the carbon
skeletons of neurotransmitters. [67] As part of this cycle, it is synthesized from glutamate and
ammonia in astrocytes and also serves as the precursor for glutamate along with alpha-
ketoglurate. [67-69]
While glutamate is recognized as an excitotoxic neurotransmitter released after TBI, patients
with brain injury are also observed to experience profound hypoglutaminemia. [67, 68, 70-95]
While the cause of this hypoglutaminemia is not known, this observed deficiency provides
rationale for dietary supplementation.
Animal studies
While many animal studies assess post-TBI glutamatergic signaling, in a rat TBI model,
glutamine administration was shown to decrease concentrations of pro-inflammatory cyto‐
kines and apoptotic cells in gastrointestinal tissue, thus reducing TBI-associated damage to
gastrointestinal mucosa. [65, 66]
Clinical studies
Limited clinical studies have associated glutamine and alanine dietary supplementation with
lower mortality rates, shorter hospital lengths of stay, decreased occurrences of pneumonia
and stress ulcers, and higher lymphocyte counts in TBI patients. [96] While these results have
been linked to an improved immunological response, future basic science and clinical studies
are needed to advance our understanding of the translational potential of glutamine as a
nutritional adjuvant in TBI therapy.
As a potential limitation of glutamine therapy, glutaminergic signaling has been implicated
in basic science studies with post-traumatic epilepsy. [97] Additionally and perhaps of greater
relevance, the recent REDOXS (REducing Deaths due to OXidative Stress) trial sought to
investigate the effect of nutritional supplementation in critically-ill patients. A randomized
trial, the study found that glutamine supplementation actually resulted in increased harm and
mortality in critically ill patients and cautiously advocated that administration of glutamine
be reserved for burn and trauma patients not in multiorgan failure. [98] Of note, much of the
glutamine in that study was administered in parenteral form, and the body of literature using
enteral glutamine has shown no such outcome.
8. Antioxidants
Biologic pathways
Reactive oxygen and nitrogen species (ROS/RNS, respectively) play an integral role in brain
injury and posttraumatic neuronal degeneration. [99, 100] In the setting of acute traumatic
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stress, endogenous protective mechanisms such as glutathione (GSH) and superoxide
dismutase (SOD) may become overwhelmed by increased production of free radicals. [99] This
is driven in part by influx of excess of intracellular calcium into mitochondria. Lipid peroxi‐
dation mediated by oxygen radical species has been suggested as an important factor in
posttraumatic neuronal degeneration. [100] In addition to disrupting the membrane phos‐
pholipid architecture, lipid peroxidation contributes to the formation of cytotoxic aldehyde-
containing byproducts that bind to and impair the function of cellular proteins. [101] The
oxidation of DNA and proteins then may trigger programmed cell death. This process is
exacerbated during the reperfusion phase of injury, resulting in additional microvascular
damage and neuronal cell death.
Clinical studies
Increasing amounts of evidence point to potential effectiveness of antioxidants in modulating
the severity of TBI. [99, 100] Specifically, nutritional antioxidants may be critical in attenuating
the deleterious effects of oxidative stress in ischemia and reperfusion type injuries. [102]
Specific antioxidant agents that have been investigated in the setting of TBI include vitamin E
(alpha-tocopherol), glucocorticoid methylprednisolone, tirilazad mesylate, 21-amino-steroids,
green tea extract, ginkgo biloba extract, resveratrol, curcumin, and niacin. [100-102] In
addition, evidence points to selenium as being an effective inhibitor of ROS-mediated apop‐
totic neural precursor cell death in TBI. [103] A full discussion of these antioxidants is beyond
the scope of this chapter which focuses on immunonutrition, but several antioxidants are
worthy of special mention.
Commercially available enteral formulas frequently tout “added antioxidants,” but these
typically are vitamin C, vitamin E, and beta-carotene. In the setting of TBI, enteral nutrition
enriched with antioxidants and neuromodulatory agents seems to have some clinical benefit.
[104] Although there were no mortality differences between the control and glutamine/
probiotic enteral nutrition regimens, the glutamine/probiotic group demonstrated lower
infection rates and infections per patient, as well as shorter intensive care stays and fewer
ventilator days. [104]
The finding that plasma vitamin C levels are significantly lower in patients with brain trauma
suggests that vitamin C plays a potential role in oxidative stress related to brain injury. [105]
In addition to vitamin C, other nutritional factors may play a role in modulating oxidative
damage associated with TBI, including vitamin E (alpha-tocopherol), beta-carotene, and
coenzyme Q10. [106] Despite promising preliminary animal studies, data showing efficacy of
specific or combined micronutrient supplementation in the setting of brain injury remains
elusive. [106] A small study examining high-dose vitamin C and vitamin E showed some
promise but should be interpreted as preliminary. [107]
It has to be noted that phase III clinical trials of neuroprotective agents in TBI have been
somewhat disappointing. [108] In a multicenter trial of tirilazad mesylate in TBI, the experi‐
mental group was found to have similar mortality and neurologic recovery rates when
compared to placebo. [109] However, a subgroup analysis suggested that tirilazad mesylate
may contribute to reduced mortality in male patients with severe head injury accompanied by
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traumatic subarachnoid hemorrhage (34% tirilazad group mortality versus 43% placebo group
mortality). [109]
One trial of polyethylene glycol (PEG)-conjugated SOD in TBI patients initiated within 8
hours  of  the  injury  showed  a  trend  toward  improved  neurological  outcomes.  [110]
Subsequent larger trials failed to reproduce any beneficial  effect however.  [111] Another
agent, U-83836E, a second-generation lazaroid with non-steroidal structure, has been shown
to decrease post-injury lipid peroxidation and protein nitration and enhance preservation
of mitochondrial respiratory function and calcium buffering ability in a mouse model, and
human studies using this agent may be warranted. [112] Melatonin is another antioxidant
agent showing promise in providing neuroprotective benefits based on evidence from rat
model of TBI. [111] A number of other promising agents have been investigated, but human
evidence continues to be scarce.
Increasing amounts of evidence suggests that the most effective antioxidative approach to the
brain-injured patient should involve combined treatment with mechanistically synergistic
antioxidants. [101] Strategies within such a paradigm should include simultaneous scavenging
of lipid peroxidation-initiating free radicals, inhibition of lipid peroxidation propagation, and
removal of neurotoxic lipid peroxidation products. [101] Clinical trials with multidrug
antioxidant regimens are needed before any recommendations can be made.
9. Branched-chain amino acids
Branched-chain amino acids (BCAAs) are essential amino acids that have important roles in
energy metabolism and protein and neurotransmitter synthesis. [113] Valine, isoleucine, and
leucine comprise the BCAAs, and these entities have important roles in regulating protein
synthesis, gluconeogenesis, and energy metabolism as well as functioning as a major source
of nitrogen for producing glutamine in the brain. [113] Because of the important baseline
functions of these compounds, this would suggest that alterations in BCAA metabolism after
TBI may actually play a role in decreased energy production and neurotransmitter synthesis,
thereby contributing to TBI pathology. As such, the supplementation of BCAAs or their
metabolites may have a role in the reduction of TBI pathology and possibly outcome.
Biologic Pathways
The metabolism of BCAAs is partially regulated by protein synthesis requirements and excess
BCAAs are either catabolized or excreted. In terms of catabolism of excess BCAAs, the first
step is catalyzed by the branched-chain aminotransferase isoenzymes, mitochondrial BCATm
and cytosolic BCATc. The resulting product of this process is glutamate, which is a major
excitatory neurotransmitter as well as a precursor of alpha-ketoglutarate. The second, irrever‐
sible step in BCAA catabolism is catalyzed by the mitochondrial branched-chain α-ketoacid
dehydrogenase (BCKDC) enzyme complex. [114] BCKDC catalyzes oxidative decarboxylation
of the BCKA products of the BCAT reaction, forming NADH and the respective branched-
chain acyl CoA derivative of each BCAA. [114]




It is well-established that TBI causes cognitive impairment and altered net synaptic efficacy.
In one study where brain injured mice or sham-injured mice either consumed water or water
containing BCAAs, there was an overall cognitive improvement with a simultaneous restora‐
tion in net synaptic efficacy. [115] The major finding of this study was that dietary delivery of
BCAAs ameliorates hippocampal-dependent cognitive dysfunction together with a restora‐
tion of net synaptic efficacy after concussive brain injury, and in every animal, cognitive
improvement occurred only in conjunction with restored net synaptic efficacy. [115]
Clinical studies
Although the literature on this subject is rather sparse, there are some promising results.
It has been reported that the levels of all three BCAAs in patients with mild TBI relative
to healthy volunteers is decreased. BCAA levels are further reduced in patients with severe
TBI compared with all groups. [113] In one study, it was shown that short-term intrave‐
nous supplementation of BCAAs in rehabilitation patients with TBI enhances recovery of
cognitive  function,  induces  a  supraphysiologic  plasma content  of  BCAAs,  and increases
tyrosine plasma concentration. [116] This study also revealed that plasma amino acid levels
remained decreased in the posttraumatic rehabilitation phase (1-22 months). In this study,
40 patients with TBI were randomly assigned either intravenous BCAAs or placebo. Plasma
tyrosine concentration improved in the group given BCAA supplementation and overall
disability  improvement  was  greater  than  that  noted  in  the  placebo  group.  The  key
conclusion of the study was simply that supplementation of BCAAs in TBI restores plasma
levels to the normal range without having a negative effect on levels of precursors of brain
catecholamines and serotonin. [116]
Another study revealed that BCAA supplementation may aid in recovery from a posttraumatic
vegetative or minimally conscious state, thus reducing the risk of the vegetative state persisting
over time. [117] This study, also performed by Aquilani et al., supplemented patients for 15
days by intravenous route with either BCAAs or placebo who were either in a posttraumatic
vegetative or minimally conscious states. [117] The 15-day period of these trials is too short to
draw any meaningful conclusions regarding that adaptation of BCAAs.
Another study sought to assess the impact of plasma BCAA and tyrosine levels following
enterally-administered BCAAs; However, enteral administration failed to return plasma
BCAA levels to the normal range. [118] In addition, it was found that elevated plasma
phenylalanine was associated with decreased ICP and increased jugular venous oxygen
saturation (SjvO2), while higher plasma isoleucine and leucine levels were associated with
increased ICP and higher plasma leucine and valine were linked to decreased SjvO2. Therefore
hyperalimentation with enteral nutrition should be carefully performed to avoid harmful side
effects of amino acids while promoting improvements in brain metabolism. [118]
Summary
Although there are a small number of very preliminary but promising studies suggesting that
BCAA supplementation may be beneficial to the TBI patient, further studies are needed to
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optimize the route and dosage of supplementation and to better elucidate the side effects of
artificial supplementation such that supplementation produces no significant side effects.
10. Choline
Immediately following TBI, there is a transient period of excess cholinergic activity which may
contribute to excitotoxicity via nicotinic and muscarinic receptor subtypes. However, the
chronic phase of TBI is actually associated with decreased brain cholinergic function.
Acetylcholine acts on nicotinic and muscarinic acetylcholine receptors, and previous studies
have suggested that TBI-related deficits in alpha-7 n-acetylcholine receptor (α7 nAChR)
density may contribute to post-TBI cognitive deficits. [119] If this downregulation of α7 nACh
receptors in fact contributes to the cognitive impairment seen as a result of TBI, a therapeutic
option includes drugs or compounds that are selective agonists of α7 nAChRs and these may
be helpful in ameliorating some measures of cognitive decline. [119]
One such compound that has been shown to bind α7 nAChR is choline. [119] Choline is an
essential nutrient available from a wide variety of nutritional sources. It is an important
molecule involved in synthesis of structural cell membrane phospholipids, other signaling
molecules, and is also a precursor for acetylcholine. [120] As such, it is postulated that dietary
choline supplementation may minimize cognitive deficits, reduce brain inflammation, and
protect the penumbra.
Biologic pathways
Acetylcholine acts on nicotinic and muscarinic acetylcholine receptors, both of which are
prominently located in brain regions that are involved with attention and cognition. [119] As
previously stated, choline has been shown to be an agonist at α7 nAChRs, but not other
nicotinic receptor subtypes. α7 nAChRs are known to be involved in both excitotoxicity and
inflammatory pathways. Once TBI occurs, multiple biochemical pathways, including the
aforementioned excitotoxicity and inflammatory pathways, are set into motion which leads to
a chronic, neurodegenerative condition.
Animal studies
In one study, dietary choline supplementation was shown to significantly reduce brain injury-
induced spatial learning deficits in a rat model. Additionally, the choline-supplemented diet
helped reduce brain inflammation and spared cortical tissue. [119]
It is known that administration of cytidine-5'-diphosphate (CDP)-choline functions as a neu‐
rostimulant in neurological disorders of memory.[121] As such, its use in TBI was promis‐
ing. Dixon et al. demonstrated that chronic CDP-choline treatment can attenuate
neurological and cognitive performance deficits following TBI in rats. [122] CDP-choline
treatment also increased post-injury resistance to the memory-disrupting effects of scopola‐
mine. Exogenous administration of CDP-choline increased ACh release. [122] The mecha‐
nism of action is not definitively known, but CDP-choline may attenuate post-injury
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functional deficits by several mechanisms, including providing the ACh precursor choline to
drive up ACh synthesis, maintaining cell integrity by accelerating membrane formation,
and/or stimulating brain metabolism. [122]
Clinical studies
Like with many immunonutrients, a number of large-scale studies have shown no benefit
despite promising animal trials. Ruff et al. found that citicoline (an intermediate in the
generation of phosphatidylcholine from choline) supplementation in TBI patients did not
improve the extent or speed the recovery in patients following acute stroke. [123]
Similarly, Zafonte et al., completed the Citicoline Brain Injury Treatment Trial (COBRIT), a
phase III, double-blind study comparing citicoline versus placebo. In this trial, 1213 study
participants with complicated mild, moderate, or severe TBI were randomized to receive 2000
milligrams of citicoline or placebo daily for 90 days. The trial ran from 2007-2011 but was
terminated early due to futility. The study did not demonstrate any benefits of citicoline
treatment. [123]
Summary
Not all promising findings in the preclinical arena have been translated to success in patients.
Choline supplementation in TBI rats holds promise. However, these have not held true in the
patient models. This creates a need to understand the mechanism of how choline induces
positive results in rats. Additionally, there may be other compounds or physiologic conditions
that are necessary to allow for the beneficial effects of choline which are as of yet unknown.
11. Creatine
Creatine is a common dietary supplement, frequently used to increase strength and muscle
mass. Creatine metabolism plays a key role in ATP turnover in the metabolically active brain.
Endogenously expressed, cerebral creatine levels have been observed to decrease after TBI and
recent studies have also shown that it provides significant neuroprotection against oxidative
stress and ischemia. [124, 125] While investigations of creatine as a nutritional component of
TBI therapy have been limited to animal models, much potential exists for clinical research to
further define its translational relevance.
Biological pathways
The mechanisms of creatine-induced neuroprotection seem to be largely related to its effects
on mitochondrial bioenergetics, binding to mitochondrial creatine kinase (CK) to exert
structural protection allowing the enzyme to maintain its ability to inhibit free radical gener‐
ation. [126, 127] Creatine supplementation lowers mitochondrial membrane potentials and
reduces mitochondrial levels of reactive oxygen species (ROS) and calcium while maintaining
the levels of adenosine triphosphate (ATP). [126] Physiologically, these effects result in
inhibition of mitochondrial permeability and reduced neuronal loss. [126] Hybrid hydropho‐
bic derivatives of creatine, creatinyl amino acids, have been synthesized with the aim to
Traumatic Brain Injury230
establish better penetration across the blood-brain barrier. In vivo these compounds maintain
both their neuroprotective abilities and chemical stability. [128]
Animal studies
In experimental mouse and rat TBI models, chronic supplementation of creatine has been
shown to decrease the extent of cortical damage by as much as 36% and 50%, respectively.
[126] Compared to rats receiving a control diet, rats fed a creatine-enriched diet have also
shown decreased levels of neurochemical markers of TBI-induced acute cellular injury.[127,
129] Many of these protective effects were demonstrated to follow a dose-dependent manner
and cumulatively provide promising preclinical data to steer pilot clinical studies. [129]
12. Magnesium
Magnesium is essential for maintenance of vital cellular functions, including glycolysis,
sustaining membrane structure and function, protein synthesis and DNA replication. [130]
Magnesium also plays an important role in central nervous system following injury. It is
known that after TBI, the normal homeostatic mechanisms of magnesium are deranged,
resulting in a rapid decline in magnesium levels in the brain. [131] This disruption of normal
magnesium homeostasis has actually been shown to correlate with the severity of neurologi‐
cally-mediated behavioral deficits following injury. [132] As such, it has been postulated that
magnesium pharmacotherapy may aid in the treatment of various CNS injuries, including
ischemia and cortical lesions, and has been found to be effective in some of these arenas.
Because of the critical function of magnesium, it is also postulated that manipulation of dietary
magnesium may have an impact on the recovery of function following TBI.
Biological pathways
Magnesium plays an important role in homeostatic regulation of key pathways involved in
the delayed secondary phase of brain injury. [133] During normal physiological processes,
magnesium is a noncompetitive inhibitor of the NMDA receptors, thereby regulating calcium
influx. [134] Following acute brain injury, tissue magnesium is depleted, leading to loss of
homeostatic control of the NMDA receptors. The ensuing massive influx of calcium leads to
neuronal degeneration and cell death. [133]
Animal studies
Previous research has shown that dietary magnesium deficiency prior to injury worsens
recovery of function and that systemic administration of magnesium pre- or post-injury
significantly improves functional recovery. A number of studies in rats have shown that
treatment with magnesium after brain injury did offer neuroprotection. [133, 135-137] Bareyre
et al. showed that in addition to beneficial effects on behavioral outcomes, magnesium
supplementation in brain-injured rats attenuated cortical histological damage. [138] Magne‐
sium therapy administered up to 24 hours after injury in rats significantly improved motor
outcome and behavioral parameters in rats with severe diffuse traumatic axonal brain injury.
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[139] Additionally, magnesium supplementation was shown to reduce long-term motor and
cognitive deficits after TBI in rats which may result in decreased post-traumatic stress and
anxiety. [140]
Clinical studies
Disruption of magnesium homeostasis has been observed in human traumatic brain injury.
Despite a number of preclinical studies showing beneficial effects of magnesium supplemen‐
tation in TBI, mostly in rat models, clinical studies in TBI patients have failed to show a
consistent clinical benefit. Temkin et al. showed that continuous infusions of magnesium
for 5 days given to patients within 8 hours of moderate or severe TBI were not neuropro‐
tective and may even have a negative effect in the treatment of significant head injury. [141]
However,  in  another  prospective  clinical  trial  by  Dhandapani  et  al.,  magnesium sulfate
administered to TBI patients within 12 hours of their injuries produced decreased mortali‐
ty and improved neurologic patient outcome. [142] There have been a number of studies
looking at the role of magnesium supplementation in combination with other pharmacolog‐
ical agents or physiological interventions, such as hypothermia and hyperoxia, again with
varied results in both preclinical and clinical trials. A recent meta-analysis of all random‐
ized controlled trials comparing magnesium supplementation in patients following acute
TBI  shows no evidence  to  support  the  use  of  magnesium beyond standard physiologic
replacement. [143]
Summary
The success of magnesium in attenuating the process of neurodegeneration in animal models
of brain injury has been widely studied with promising results. Unfortunately, these preclinical
successes have not consistently translated into success in humans. Magnesium supplementa‐
tion in TBI patients has produced varied results, requiring further investigation into not only
magnesium supplementation but the secondary parameters that may affect clinical outcome
in TBI patients.
13. Vitamin D
Vitamin D hormone (VDH; 1, 25-dihydroxyvitamin D3) is recognized as a neurosteroid with
downstream implications in many different CNS signaling cascades. [144] VDH deficiency is
associated with dysregulated neuronal physiology and has been demonstrated to both
exacerbate TBI and reduce the efficacy of progesterone treatment for TBI. [145-147]. The
relationship between VDH and TBI is perhaps most important in aging populations, within
which the former is high in prevalence and the latter is rising in incidence. [148, 149]
Biological pathways
With regards to TBI, vitamin D generally acts in an anti-inflammatory manner, by regulating
intracellular calcium levels (hence reducing the effects of glutamate excitotoxicity) and
enhancing free radical scavenging. [144] Much TBI-related vitamin D research investigates it
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as a combined therapy with progesterone. The two hormones are proposed to act in a syner‐
gistic and perhaps compensatory manner, each of them having their own anti-inflammatory
and oxidative damage-reducing properties. [144] Together, VDH and progesterone stimulate
neural growth in cultured neurons following in vitro glutamate excitotoxicity. [145, 147]
Animal studies
In rat cortical contusion injury (CCI) models of TBI, combined therapy consisting of VDH and
progesterone resulted in reduced expression of inflammatory genes; protection against cell
death and DNA damage; and significant improvement in post-traumatic behavior in VDH-
deficient rats. [148, 149]
Clinical studies
Limited clinical trials have shown promising results for VDH and progesterone combination
therapy, improving outcomes and decreasing mortality rates after TBI. [144] VDH has a high
safety profile and is inexpensive and easily administered. [147] Continued investigations will
be critical to further elucidate its specific mechanisms of actions, differences in combination
therapy and monotherapy, and potential for use in a therapeutic or preventative manner.
14. Zinc and other trace elements
Trace elements are known to be important modulators of cell physiology and growth,
contributing to many key processes such as wound healing and the immune response. [150]
Among trace elements, zinc is specifically critical for tissue repair and essential for the function
of many enzymes and gene expression. [151, 152] The majority of zinc ions in the brain are
bound to proteins while the remaining are sequestered in presynaptic neuronal vesicles. [151]
Although neurotoxic at high levels, zinc mediates synaptic transmission and plasticity, and
clinical studies have shown that after TBI patients lose excess zinc in urine in proportion to
injury severity and are at increased risk for developing zinc deficiency. [152, 153] Dietary zinc
regulates intestinal zinc absorption and plays an important role in zinc homeostasis, thus
making zinc promising as a possible nutritional adjunct to TBI therapy. [154]
Biological pathways
To a large degree, there is some debate with regards to whether zinc is neuroprotective or
neurotoxic. [155] Many studies have demonstrated zinc accumulation after brain injury,
associating it with neurodegeneration and deposited aggregates of ubiquitinated proteins and
thus linking altered zinc homeostasis to impaired protein degradation. [153, 156-160] Though
zinc chelators were able to block these TBI-induced histological changes, they did not lead to
improved post-TBI outcomes in rats. [152, 153]
Contrarily, the neuroprotective effects of zinc are also established at the basic science and
animal model levels. After mechanical repetitive strain injury (RSI), neuronal-like cells have
been shown to develop a cellular zinc deficiency, and zinc deficiency itself has been linked to
impaired neuronal stem cell proliferation and compromised cellular repair. [161, 162]




In animal models, zinc reduces the development of behavioral deficits after TBI. [153, 163]
Specifically, in a rat controlled cortical impact (CCI) model, zinc supplementation reduced
anxiety and cognitive impairments. [153, 161, 163] This supplementation did not lead to
increased neuronal cell death. [161] Further evidence of its potential therapeutic benefit comes
from the fact that zinc deficiency has been demonstrated to result in increased cell death and
altered glial immune responses in several different rat and mouse TBI models. [151, 153, 164,
165]
Clinical studies
Limited preclinical studies show that, after an initial period of total parenteral nutrition,
dietary zinc supplementation of 22 milligrams per day using zinc gluconate significantly
increases visceral protein mass in post-TBI patients, is associated with improved Glasgow
Coma Scores, as well as mortality decrease from 26% to 12%. [153] With the recommended
upper limit of dietary zinc being 40 milligrams per day, further clinical studies will clearly
define the optimal doses and time windows to improve post-TBI deficits and prevent neuro‐
toxicity and undesired effects to other organs. [153, 166]
Other trace elements
While zinc has been the most thoroughly studied trace element in the contexts of TBI therapy,
few studies have investigated the potential roles of others. While most of these elements still
present the same concerns of toxicity versus protection, preliminary results seem promising
for continued research. [154]
• As described above for zinc, copper deficiency has also been linked to increased neuronal
apoptosis in a rat model of TBI. [165]
• To prevent deposition of free iron from heme degradation, administration of heme oxy‐
genase (HO) inhibitors such as tin protoporphyrin or iron chelators have shown to reduce
pathophysiologic and neuromotor changes in post-TBI models. [167, 168]
• As mentioned previously in this chapter, selenium, acting as an antioxidant, reduces reactive
oxygen species (ROS)-mediated apoptosis of neural precursor cells both in vitro and in a
mouse model of TBI. [103]
15. Conclusion
TBI represents a heterogeneous pathophysiological process that is clearly a challenge to
manage. Multiple clinical studies of nutritional strategies have not defined a specific pathway
that can serve as a sole, standalone target in TBI nutritional therapy. Multidimensional
treatment plans, perhaps incorporating some of the described nutritional adjuvants, will thus
merit more investigations from both the bench and the bedside to elucidate effective strategies
to best treat TBI patients. Unfortunately, many strategies that are promising in the lab or in
animal models have not borne fruit in clinical trials to date.
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